Aug 31, 2017 20:35 pm UTC| Business
IRVINE, Calif., Aug. 31, 2017 -- Khang Khang LLP (the “Firm”) announces a securities class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL). Investors who purchased or otherwise...
New EFI Fiery Integration with Kodak PRINERGY Workflow 8 Expands Customer Capability
Aug 31, 2017 20:34 pm UTC| Business
FREMONT, Calif., Aug. 31, 2017 -- Electronics For Imaging, Inc. (Nasdaq:EFII), a world leader in customer-focused digital printing innovation, is continuing to evolve the integration between the new Kodak™ PRINERGY™...
World’s Largest Gathering of Precious Commodity Investors and Equities to Meet in Colorado Springs
Aug 31, 2017 20:32 pm UTC| Business
DENVER, Aug. 31, 2017 -- Now in its 28th year, the Denver Gold Forum (DGF) http://www.denvergoldforum.org is the world’s oldest and largest gathering of precious commodity equities. Presented every year since 1989, the...
Aug 31, 2017 20:32 pm UTC| Business
NEW YORK, Aug. 31, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of HD Supply Holdings, Inc. (NASDAQ:HDS) who purchased shares between November 9, 2016 and...
Houston-Area Teachers Unite to Help Students Displaced During Hurricane Harvey
Aug 31, 2017 20:32 pm UTC| Business
HOUSTON, Aug. 31, 2017 -- Teachers Volunteering in Shelters, a newly formed group of Houston-area teachers, is organizing to help children in the flood-ravaged areas of Southeast Texas brought on by Hurricane Harvey. In...
NV5 Provides Geotechnical Engineering Services to Amazon
Aug 31, 2017 20:30 pm UTC| Business
HOLLYWOOD, Fla., Aug. 31, 2017 -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq:NVEE), a provider of professional and technical engineering and consulting solutions, announced today that it was selected to perform...
MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen
Aug 31, 2017 20:30 pm UTC| Business
ROCKVILLE, MD, Aug. 31, 2017 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment...